Ann Intern Med. 2016 Mar 1;164(5):360-6. doi: 10.7326/M15-2957. Epub 2016 Feb 9.
Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents.
The USPSTF reviewed the evidence on the benefits and harms of screening; the accuracy of primary care-feasible screening tests; and the benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years.
This recommendation applies to children and adolescents aged 18 years or younger who do not have a diagnosis of MDD.
The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged 11 years or younger. (I statement).
美国预防服务工作组(USPSTF)对儿童和青少年重度抑郁症(MDD)筛查建议的更新。
USPSTF 审查了筛查的益处和危害、初级保健可行的筛查测试的准确性,以及在 7 至 18 岁患者中进行心理治疗、药物治疗和协作式护理模式治疗的益处和危害。
本建议适用于未被诊断为 MDD 的 18 岁或以下的儿童和青少年。
USPSTF 建议对 12 至 18 岁的青少年进行 MDD 筛查。筛查应在适当的系统到位的情况下进行,以确保准确的诊断、有效的治疗和适当的随访。(B 级推荐)USPSTF 得出结论,目前的证据不足以评估对 11 岁及以下儿童 MDD 筛查的利弊平衡。(I 声明)。